Jubilant Biosys Innovative Research Services Pte Limited (JBIRSPL), a subsidiary of Jubilant Biosys Limited and a wholly owned subsidiary of Jubilant Pharmova Limited, has successfully completed the acquisition of Pierre Fabre SA’s R&D center in Saint Julien, France. This acquisition was carried out through JASMIN, a newly incorporated entity in France, with JBIRSPL subscribing to 80% of its equity capital while the remaining 20% is retained by Pierre Fabre.
Following the closure of the transaction, the entity has been renamed Jubilant Biosys France. This move marks a significant expansion of Jubilant Biosys’ global footprint in the pharmaceutical research and development sector. The agreements, including the shareholders’ agreement and other transition agreements, were executed between JBIRSPL and Pierre Fabre SA, along with its affiliated entities.
The acquisition further strengthens Jubilant Pharmova’s capabilities in innovative drug discovery and contract research services. The event was officially recorded on March 19, 2025, at 11:54 PM IST. The company has requested regulatory authorities to take note of this transaction.
This acquisition aligns with Jubilant Pharmova’s long-term vision of enhancing its global R&D capabilities and fostering innovation in pharmaceutical research.
